Anti-CD89 Monoclonal Antibody (Clone:A59)-FITC Conjugated

Anti-CD89 Monoclonal Antibody (Clone:A59)-FITC Conjugated
Artikelnummer Größe Datenblatt Manual SDB Lieferzeit Menge Preis
ABE-30-1923-100 100 tests -

3 - 11 Werktage*

653,00 €
 
CD89 (Fc-alpha-R) is a type I transmembrane glycoprotein serving as a receptor for IgA. Soluble... mehr
Produktinformationen "Anti-CD89 Monoclonal Antibody (Clone:A59)-FITC Conjugated"
CD89 (Fc-alpha-R) is a type I transmembrane glycoprotein serving as a receptor for IgA. Soluble CD89 is detectable in serum and retains its IgA binding capacity. For signal transduction the association with FcR gamma chain homodimers is needed. CD89 is expressed on granulocytes, monocytes, macrophages, dendritic cells and myeloid cell lines. Its expression is upregulated in presence of IgA immune complexes, stimulators (such as LPS, PMA), TNF alpha, IL1 beta or GM-CSF, and it is downregulated in presence of TGF beta and suramin. Binding of IgA-opsonized targets to CD89 leads to phagocytic and cytotoxic processes of the immunologic defense. Protein function: Binds to the Fc region of immunoglobulins alpha. Mediates several functions including cytokine production. [The UniProt Consortium]
Schlagworte: Anti-CD89, Anti-FCAR, Anti-IgA Fc receptor, Anti-Immunoglobulin alpha Fc receptor, Anti-CD89 Monoclonal Antibody (Clone:A59)-FITC Conjugated
Hersteller: Abeomics
Hersteller-Nr: 30-1923

Eigenschaften

Anwendung: FC
Antikörper-Typ: Monoclonal
Klon: A59
Konjugat: FITC
Wirt: Mouse
Spezies-Reaktivität: human, non-human primates
Immunogen: Ag8.653 myeloma cells

Handhabung & Sicherheit

Lagerung: +4°C
Versand: +4°C (International: +4°C)
Achtung
Nur für Forschungszwecke und Laboruntersuchungen: Nicht für die Anwendung im oder am Menschen!
Hier kriegen Sie ein Zertifikat
oder , um Analysenzertifikate anzufordern.
Bewertungen lesen, schreiben und diskutieren... mehr
Kundenbewertungen für "Anti-CD89 Monoclonal Antibody (Clone:A59)-FITC Conjugated"
Bewertung schreiben
oder , um eine Produktbewertung abzugeben.
Zuletzt angesehen